In vitro susceptibility to everninomycin of gram-positive nosocomial pathogens isolated from intensive care units in Germany

Chemotherapy

Volumn 47, Issue 1, 2001, Pages 15-18

  Kropec, Andrea ^a   Frank, Uwe ^a   Jonas, Daniel ^a   Thriene, Wolfgang ^a   Schmidt Eisenlohr, Elke ^a   Daschner, Franz Dieter ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Everninomycin; Gram positive pathogens; In vitro susceptibility; Intensive care units; Nosocomial infections

Indexed keywords

EVERNINOMICIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; COAGULASE NEGATIVE STAPHYLOCOCCUS; CROSS RESISTANCE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GERMANY; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG RESISTANCE, MICROBIAL; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS;

EID: 0035184141     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000048496     Document Type: Article

References (24)

1. Nosocomial infections in intensive care units
2. Prevalence of nosocomial infections in representative German hospitals
3. An analysis of two prevalence surveys of nosocomial infection in German intensive care units
4. Nosocomial infections in medical intensive care units in the United States
5. Predominant pathogens in hospital infections
6. Nosocomial infections in coronary care units in the United States
7. Prolongation of hospital stay by nosocomial pneumonia and wound infection
8. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: The role of streptogramins and other newer compounds
9. Everninomicin, a new oligosaccharide antibiotic: Its antimicrobial activity, post-antibiotic effect and synergistic bactericidal activity
10. Comparative in vitro activity of SCH 27899, a novel everninomicin, and vancomycin
11. Association between decreased susceptibility to a new antibiotic for treatment of human diseases, everninomicin (SCH 27899), and resistance to an antibiotic used for growth promotion in animals, avilamycin
12. Antimicrobial activity of SCH27899 (Ziracin), a novel everninomicin derivative, tested against Streptococcus spp.: Disk diffusion/etest method evaluations and quality control guidelines
13. Antimicrobial activity and spectrum of SCH27899 (Ziracin) tested against gram-positive species including recommendations for routine susceptibility testing methods and quality control
14. In vitro activity of vancomycin and teicoplanin against Staphylococcus aureus and Staphylococcus epidermis colonizing catheters
15. Glycopeptides in the treatment of staphylococcal infections
16. High-level vancomycin-resistant enterococci causing hospital infections
17. Multidrug-resistant Enterococcus faecium. An untreatable nosocomial pathogen
18. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin
19. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan
20. Heterogeneously vancomycin-resistant Staphylococcus epidermidis strain causing recurrent peritonitis in a dialysis patient during vancomycin therapy
21. Vancomycin-resistant Staphylococcus aureus: Infection control considerations
22. Wie gross ist die potentielle Gefahr durch Vancomycin-resistente Enterokokken?
23. Preliminary interpretive criteria for disk diffusion susceptibility testing of SCH 27899, a compound in the everninomicin class of antimicrobial agents